CommercialPrior AuthHigh impact
Biosimilars: Infliximab Update
Blue Cross Blue Shield of Kansas·KS · Rheumatology, Gastroenterology, Dermatology·Provider News
Effective date
Apr 1, 2023
We identified it
Jun 19, 2026
Summary
BCBSKS is changing their preferred infliximab biosimilars to Avsola and Inflectra effective April 1, 2023. Providers using preferred products (Avsola, Inflectra) will not need prior authorization, while non-preferred products (Remicade, Renflexis) will require prior authorization.
Action Required
By April 1, 2023: Billing team must update prior authorization workflows to require PA for Remicade and Renflexis infliximab products while removing PA requirements for Avsola and Inflectra. Update encounter forms and provider alerts to indicate preferred products. Providers should be notified to switch patients to preferred biosimilars when clinically appropriate to avoid PA delays.